Business
Appointment of CMO and Medical Director
Appointment of CMO and Medical Director.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6038F\n Scancell Holdings Plc\n 17 November 2020\n \n \n \n \n 17 November 2020\n \n \n \n \n \n Scancell Holdings plc\n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n Appointment of Dr Gillies O'Bryan-Tear as \n \n Chief Medical Officer and Dr Robert Miller as Medical Director\n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce the appointments of Dr Gillies O'Bryan-Tear to the position of Chief Medical Officer and Dr Robert Miller to Medical Director. Today's appointments reflect Scancell's continuing focus on advancing the clinical development and commercialisation of its programmes for the treatment of cancer and in developing a vaccine for COVID-19.\n \n \n \n \n \n Dr Gillies O'Bryan-Tear has over 30 years' experience in the pharmaceutical industry, spanning clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotechnology companies, in the US and Europe, and has been involved in multiple product approvals. In 2009 he became Chief Medical Officer of Algeta, a listed Norwegian biotech company developing a radiopharmaceutical for prostate cancer, which was launched worldwide in 2013. Algeta was subsequently acquired in 2014 by Bayer for $2.9 billion. Following the acquisition, Dr O'Bryan-Tear has been a retained adviser to a number of global biotechnology companies including Audentes before its acquisition by Astellas, as well as Fusion Pharmaceuticals and Clarity Pharmaceuticals. \n \n \n \n \n \n Gillies is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and is Chair of its Policy and Communications Group, as well as a Fellow of the Royal College of Physicians. He obtained his MD degree from the University of Cambridge and University College Hospital, London and trained in internal medicine and oncology in the UK.\n \n \n \n \n \n Dr Robert Miller is a Managing Partner in Artemida Pharma, a drug development consultancy and has represented a number of companies providing strategic expertise, medical management and clinical development support for both small and large pharmaceutical and biotechnology companies during his 30-year career in...